A study presented at ACR Convergence 2025 has sparked interest among doctors and patients alike. Drugs originally made for ...

CHICAGO -- Hitting rheumatoid arthritis (RA) early and hard, with targeted therapies as first-line treatment, appears to ...

New research presented at ACR 2025 shows GLP-1 receptor agonists, used for diabetes and obesity, may reduce rheumatoid ...

The study also presented the first external validation and use in patients with early RA of six proposed screening strategies ...

Several factors — but not older age — increased infection risk with the use of non-TNF biologics following first-line ...

The new biotech Elevara plans to initiate Phase II testing of its lead candidate ELV001 as an add-on treatment for rheumatoid ...

An investigational monoclonal antibody drug targeting the PD-1 ligand on T cells was a winner in a phase II rheumatoid ...

Electra Therapeutics has garnered the funds it needs to complete a pivotal trial of its lead drug, angling to become the ...

A study presented at ACR Convergence 2025 suggests that GLP 1 receptor agonists reduce flares and systemic inflammation in Rheumatoid Arthritis (RA) patients.

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the ...

In the absence of much federal action, states have enacted dozens of laws this year to lower prescription drug costs for ...

Long-term flare risk and remission rates did not differ between patients with well-controlled RA who tapered vs continued MTX therapy.